Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
PhD, E A dos Gilmar Reis, Eduardo Augusto Dos Santos Moreira-Silva, Daniela Carla Medeiros Silva, Prof Lehana Thabane, Aline Cruz Milagres, Thiago Santiago Ferreira, Castilho Vitor Quirino Dos Santos, Vitoria Helena De Souza Campos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes De Almeida, Eduardo Diniz Callegari, Adhemar Dias De Figueiredo Neto, Leonardo Cançado Monteiro Savassi, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Ofir Harari, Jamie I Forrest, Hinda Ruton, Sheila Sprague, Paula Mckay, Alla V Glushchenko, Craig R Rayner, Eric J Lenze, Angela M Reiersen, Gordon H Guyatt, Dr Edward J Mills
The Lancet Global Health, doi:10.1016/s2214-109x(21)00448-4
Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19. Methods This placebo-controlled, randomised, adaptive platform trial done among high-risk symptomatic Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients from 11 clinical sites in Brazil with a known risk factor for progression to severe disease. Patients were randomly assigned (1:1) to either fluvoxamine (100 mg twice daily for 10 days) or placebo (or other treatment groups not reported here). The trial team, site staff, and patients were masked to treatment allocation. Our primary outcome was a composite endpoint of hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19 up to 28 days postrandom assignment on the basis of intention to treat. Modified intention to treat explored patients receiving at least 24 h of treatment before a primary outcome event and per-protocol analysis explored patients with a high level adherence (>80%). We used a Bayesian analytic framework to establish the effects along with probability of success of intervention compared with placebo. The trial is registered at ClinicalTrials.gov (NCT04727424) and is ongoing. Findings The study team screened 9803 potential participants for this trial. The trial was initiated on June 2, 2020, with the current protocol reporting randomisation to fluvoxamine from Jan 20 to Aug 5, 2021, when the trial arms were stopped for superiority. 741 patients were allocated to fluvoxamine and 756 to placebo. The average age of participants was 50 years (range 18-102 years); 58% were female. The proportion of patients observed in a COVID-19 emergency setting for more than 6 h or transferred to a teritary hospital due to COVID-19 was lower for the fluvoxamine group compared with placebo (79 [11%] of 741 vs 119 [16%] of 756); relative risk [RR] 0•68; 95% Bayesian credible interval [95% BCI]: 0•52-0•88), with a probability of superiority of 99•8% surpassing the prespecified superiority threshold of 97•6% (risk difference 5•0%). Of the composite primary outcome events, 87% were hospitalisations. Findings for the primary outcome were similar for the modified intention-to-treat analysis (RR 0•69, 95% BCI 0•53-0•90) and larger in the per-protocol analysis (RR 0•34, 95% BCI, 0•21-0•54). There were 17 deaths in the fluvoxamine group and 25 deaths in the placebo group in the primary intention-to-treat analysis (odds ratio [OR] 0•68, 95% CI: 0•36-1•27). There was one death in the fluvoxamine group and 12 in the placebo group for the perprotocol population (OR 0•09; 95% CI 0•01-0•47). We found no significant differences in number of treatment..
References
Anderson, Fluvoxamine, melatonin and COVID-19, Psychopharmacology (Berl)
Angus, Derde, Al-Beidh, Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial, JAMA
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Hoertel, Sánchez-Rico, Vernet, Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry,
doi:10.1038/s41380-021-01021-4Horby, Pessoa-Amorim, Peto, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Ishima, Fujita, Hashimoto, Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells, Eur J Pharmacol
Lenze, Mattar, Zorumski, Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA
Omi, Tanimukai, Kanayama, Fluvoxamine alleviates ER stress via induction of sigma-1 receptor, Cell Death Dis
Pan, Peto, Henao-Restrepo, Repurposed antiviral drugs for Covid-19 -interim WHO Solidarity Trial results, N Engl J Med
Park, Siden, Zoratti, Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols, Trials
Pashaei, Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives?, J Clin Neurosci
Rayner, Dron, Park, Accelerating clinical evaluation of repurposed combination therapies for COVID-19, Am J Trop Med Hyg
Reis, Silva Eadsm, Silva, A multi-center, adaptive, randomized, platform trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol, Gates Open Res
Reis, Silva, Silva, Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial, JAMA Netw Open
Rosen, Seki, Fernández-Castañeda, Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis, Sci Transl Med
Schlienger, Meier, Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?, Am J Cardiovasc Drugs
Siemieniuk, Bartoszko, Ge, Drug treatments for covid-19: living systematic review and network meta-analysis, BMJ
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: a review of its mechanism of action and its role in COVID-19,
doi:10.17605/OSF.IO/EG37XTorres, Artaza, Profeta, Alonso, Kang, COVID-19 vaccination: returning to WHO's Health For All, Lancet Glob Health
Wang, Levi, Ellis, Hill, Minimum manufacturing costs, national prices and estimated global availability of new repurposed therapies for COVID-19, medRxiv,
doi:10.1101/2021.06.01.21258147Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Who, World Health Organization model list of essential medicines: 21st list 2019
Woodcock, Lavange, Master protocols to study multiple therapies, multiple diseases, or both, N Engl J Med
Yu, Bafadhel, Dorward, Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet
{ 'indexed': {'date-parts': [[2024, 4, 5]], 'date-time': '2024-04-05T08:29:04Z', 'timestamp': 1712305744841},
'reference-count': 24,
'publisher': 'Elsevier BV',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2022, 1, 1]],
'date-time': '2022-01-01T00:00:00Z',
'timestamp': 1640995200000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2021, 9, 24]],
'date-time': '2021-09-24T00:00:00Z',
'timestamp': 1632441600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es',
'clinicalkey.com', 'thelancet.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 1]]},
'DOI': '10.1016/s2214-109x(21)00448-4',
'type': 'journal-article',
'created': { 'date-parts': [[2021, 10, 28]],
'date-time': '2021-10-28T06:18:26Z',
'timestamp': 1635401906000},
'page': 'e42-e51',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 272,
'title': 'Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among '
'patients with COVID-19: the TOGETHER randomised, platform clinical trial',
'prefix': '10.1016',
'volume': '10',
'author': [ {'given': 'Gilmar', 'family': 'Reis', 'sequence': 'first', 'affiliation': []},
{ 'given': 'Eduardo Augusto',
'family': 'dos Santos Moreira-Silva',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Daniela Carla Medeiros',
'family': 'Silva',
'sequence': 'additional',
'affiliation': []},
{'given': 'Lehana', 'family': 'Thabane', 'sequence': 'additional', 'affiliation': []},
{'given': 'Aline Cruz', 'family': 'Milagres', 'sequence': 'additional', 'affiliation': []},
{'given': 'Thiago Santiago', 'family': 'Ferreira', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Castilho Vitor Quirino',
'family': 'dos Santos',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Vitoria Helena',
'family': 'de Souza Campos',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Ana Maria Ribeiro',
'family': 'Nogueira',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Ana Paula Figueiredo Guimaraes',
'family': 'de Almeida',
'sequence': 'additional',
'affiliation': []},
{'given': 'Eduardo Diniz', 'family': 'Callegari', 'sequence': 'additional', 'affiliation': []},
{ 'given': 'Adhemar Dias',
'family': 'de Figueiredo Neto',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Leonardo Cançado Monteiro',
'family': 'Savassi',
'sequence': 'additional',
'affiliation': []},
{ 'given': 'Maria Izabel Campos',
'family': 'Simplicio',
'sequence': 'additional',
'affiliation': []},
{'given': 'Luciene Barra', 'family': 'Ribeiro', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rosemary', 'family': 'Oliveira', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ofir', 'family': 'Harari', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jamie I', 'family': 'Forrest', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hinda', 'family': 'Ruton', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sheila', 'family': 'Sprague', 'sequence': 'additional', 'affiliation': []},
{'given': 'Paula', 'family': 'McKay', 'sequence': 'additional', 'affiliation': []},
{'given': 'Alla V', 'family': 'Glushchenko', 'sequence': 'additional', 'affiliation': []},
{'given': 'Craig R', 'family': 'Rayner', 'sequence': 'additional', 'affiliation': []},
{'given': 'Eric J', 'family': 'Lenze', 'sequence': 'additional', 'affiliation': []},
{'given': 'Angela M', 'family': 'Reiersen', 'sequence': 'additional', 'affiliation': []},
{'given': 'Gordon H', 'family': 'Guyatt', 'sequence': 'additional', 'affiliation': []},
{'given': 'Edward J', 'family': 'Mills', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/S2214-109X(21)00448-4_bib1',
'doi-asserted-by': 'crossref',
'first-page': 'e1355',
'DOI': '10.1016/S2214-109X(20)30415-0',
'article-title': "COVID-19 vaccination: returning to WHO's Health For All",
'volume': '8',
'author': 'Torres',
'year': '2020',
'journal-title': 'Lancet Glob Health'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib2',
'doi-asserted-by': 'crossref',
'first-page': '1364',
'DOI': '10.4269/ajtmh.20-0995',
'article-title': 'Accelerating clinical evaluation of repurposed combination therapies '
'for COVID-19',
'volume': '103',
'author': 'Rayner',
'year': '2020',
'journal-title': 'Am J Trop Med Hyg'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib3',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/cddis.2014.301',
'article-title': 'Fluvoxamine alleviates ER stress via induction of sigma-1 receptor',
'volume': '5',
'author': 'Omi',
'year': '2014',
'journal-title': 'Cell Death Dis'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib4',
'doi-asserted-by': 'crossref',
'DOI': '10.3389/fphar.2021.652688',
'article-title': 'Fluvoxamine: a review of its mechanism of action and its role in '
'COVID-19',
'volume': '12',
'author': 'Sukhatme',
'year': '2021',
'journal-title': 'Front Pharmacol'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib5',
'doi-asserted-by': 'crossref',
'DOI': '10.1038/s41380-021-01021-4',
'article-title': 'Association between antidepressant use and reduced risk of intubation '
'or death in hospitalized patients with COVID-19: results from an '
'observational study',
'author': 'Hoertel',
'year': '2021',
'journal-title': 'Mol Psychiatry'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib6',
'doi-asserted-by': 'crossref',
'first-page': '2292',
'DOI': '10.1001/jama.2020.22760',
'article-title': 'Fluvoxamine vs placebo and clinical deterioration in outpatients with '
'symptomatic COVID-19: a randomized clinical trial',
'volume': '324',
'author': 'Lenze',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib7',
'doi-asserted-by': 'crossref',
'first-page': '572',
'DOI': '10.1186/s13063-019-3664-1',
'article-title': 'Systematic review of basket trials, umbrella trials, and platform '
'trials: a landscape analysis of master protocols',
'volume': '20',
'author': 'Park',
'year': '2019',
'journal-title': 'Trials'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib8',
'doi-asserted-by': 'crossref',
'first-page': '62',
'DOI': '10.1056/NEJMra1510062',
'article-title': 'Master protocols to study multiple therapies, multiple diseases, or '
'both',
'volume': '377',
'author': 'Woodcock',
'year': '2017',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib9',
'doi-asserted-by': 'crossref',
'first-page': '117',
'DOI': '10.12688/gatesopenres.13304.2',
'article-title': 'A multi-center, adaptive, randomized, platform trial to evaluate the '
'effect of repurposed medicines in outpatients with early coronavirus '
'disease 2019 (COVID-19) and high-risk for complications: the TOGETHER '
'master trial protocol',
'volume': '5',
'author': 'Reis',
'year': '2021',
'journal-title': 'Gates Open Res'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib10',
'doi-asserted-by': 'crossref',
'first-page': '611',
'DOI': '10.1007/s00213-020-05753-z',
'article-title': 'Fluvoxamine, melatonin and COVID-19',
'volume': '238',
'author': 'Anderson',
'year': '2021',
'journal-title': 'Psychopharmacology (Berl)'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib11',
'doi-asserted-by': 'crossref',
'first-page': '497',
'DOI': '10.1056/NEJMoa2023184',
'article-title': 'Repurposed antiviral drugs for Covid-19 - interim WHO Solidarity Trial '
'results',
'volume': '384',
'author': 'Pan',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib12',
'doi-asserted-by': 'crossref',
'DOI': '10.1001/jamanetworkopen.2021.6468',
'article-title': 'Effect of early treatment with hydroxychloroquine or lopinavir and '
'ritonavir on risk of hospitalization among patients with COVID-19: the '
'TOGETHER randomized clinical trial',
'volume': '4',
'author': 'Reis',
'year': '2021',
'journal-title': 'JAMA Netw Open'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib13',
'doi-asserted-by': 'crossref',
'first-page': '843',
'DOI': '10.1016/S0140-6736(21)01744-X',
'article-title': 'Inhaled budesonide for COVID-19 in people at high risk of complications '
'in the community in the UK (PRINCIPLE): a randomised, controlled, '
'open-label, adaptive platform trial',
'volume': '398',
'author': 'Yu',
'year': '2021',
'journal-title': 'Lancet'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib14',
'doi-asserted-by': 'crossref',
'first-page': '163',
'DOI': '10.1016/j.jocn.2021.03.010',
'article-title': 'Drug repurposing of selective serotonin reuptake inhibitors: could '
'these drugs help fight COVID-19 and save lives?',
'volume': '88',
'author': 'Pashaei',
'year': '2021',
'journal-title': 'J Clin Neurosci'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib15',
'doi-asserted-by': 'crossref',
'first-page': '167',
'DOI': '10.1016/j.ejphar.2014.01.064',
'article-title': 'Interaction of new antidepressants with sigma-1 receptor chaperones and '
'their potentiation of neurite outgrowth in PC12 cells',
'volume': '727',
'author': 'Ishima',
'year': '2014',
'journal-title': 'Eur J Pharmacol'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib16',
'doi-asserted-by': 'crossref',
'DOI': '10.1126/scitranslmed.aau5266',
'article-title': 'Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in '
'preclinical models of inflammation and sepsis',
'volume': '11',
'author': 'Rosen',
'year': '2019',
'journal-title': 'Sci Transl Med'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib17',
'doi-asserted-by': 'crossref',
'first-page': '149',
'DOI': '10.2165/00129784-200303030-00001',
'article-title': 'Effect of selective serotonin reuptake inhibitors on platelet '
'activation: can they prevent acute myocardial infarction?',
'volume': '3',
'author': 'Schlienger',
'year': '2003',
'journal-title': 'Am J Cardiovasc Drugs'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib18',
'article-title': 'Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): '
'preliminary results of a randomised, controlled, open-label, platform '
'trial',
'author': 'Horby',
'year': '2021',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib19',
'doi-asserted-by': 'crossref',
'first-page': '1317',
'DOI': '10.1001/jama.2020.17022',
'article-title': 'Effect of hydrocortisone on mortality and organ support in patients '
'with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain '
'randomized clinical trial',
'volume': '324',
'author': 'Angus',
'year': '2020',
'journal-title': 'JAMA'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib20',
'article-title': 'Drug treatments for covid-19: living systematic review and network '
'meta-analysis',
'volume': '370',
'author': 'Siemieniuk',
'year': '2020',
'journal-title': 'BMJ'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib21',
'article-title': 'Minimum manufacturing costs, national prices and estimated global '
'availability of new repurposed therapies for COVID-19',
'author': 'Wang',
'year': '2021',
'journal-title': 'medRxiv'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib22',
'doi-asserted-by': 'crossref',
'first-page': '229',
'DOI': '10.1056/NEJMoa2029849',
'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19',
'volume': '384',
'author': 'Chen',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib23',
'doi-asserted-by': 'crossref',
'first-page': '238',
'DOI': '10.1056/NEJMoa2035002',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'Covid-19',
'volume': '384',
'author': 'Weinreich',
'year': '2021',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/S2214-109X(21)00448-4_bib24',
'series-title': 'World Health Organization model list of essential medicines: 21st list '
'2019',
'year': '2019'}],
'container-title': 'The Lancet Global Health',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2214109X21004484?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S2214109X21004484?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2022, 8, 9]],
'date-time': '2022-08-09T09:49:09Z',
'timestamp': 1660038549000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2214109X21004484'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1]]},
'references-count': 24,
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2022, 1]]}},
'alternative-id': ['S2214109X21004484'],
'URL': 'http://dx.doi.org/10.1016/S2214-109X(21)00448-4',
'relation': {},
'ISSN': ['2214-109X'],
'subject': ['General Medicine'],
'container-title-short': 'The Lancet Global Health',
'published': {'date-parts': [[2022, 1]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Effect of early treatment with fluvoxamine on risk of emergency care and '
'hospitalisation among patients with COVID-19: the TOGETHER randomised, platform '
'clinical trial',
'name': 'articletitle',
'label': 'Article Title'},
{'value': 'The Lancet Global Health', 'name': 'journaltitle', 'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/S2214-109X(21)00448-4',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{ 'value': 'https://doi.org/10.1016/S2214-109X(21)00501-5',
'name': 'associatedlink',
'label': 'CrossRef DOI link to the associated document'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 The Author(s). Published by Elsevier Ltd.',
'name': 'copyright',
'label': 'Copyright'}]}
